AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Cancer Gene Mutation

Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer NCT07563595n/a3 sites๐Ÿ“ Freiburg im Breisgau๐Ÿ“ Paderborn๐Ÿ“ Ravensburg iOMEDICO AG ยท Tests: Elacestrant, Standard of care (Investigator Choice) Immunohistochemical Algorithm for the Diagnosis and Classification of Hepatocellular Carcinomas With TERT, TP53 and CTNNB1 Mutation NCT06718153NA1 site๐Ÿ“ Bologna IRCCS Azienda Ospedaliero-Universitaria di Bologna ยท Tests: Immunohistochemistry and in situ hybridisation analysis Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype NCT07341867Phase 11 site๐Ÿ“ Boston Andrew Hantel, MD ยท Tests: Dexamethasone, Bortezomib, LENALIDOMIDE, Daratumumab, Carboplatin A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany NCT07255638n/a12 sites๐Ÿ“ Berlin๐Ÿ“ Bochum๐Ÿ“ Deggendorf Blueprint Medicines Corporation ยท Tests: Avapritinib Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas NCT04620187Phase 213 sites๐Ÿ“ Atlanta๐Ÿ“ Chicago๐Ÿ“ Boston Dana-Farber Cancer Institute ยท Tests: Ado-trastuzumab (T) emtansine (T-DM1), Standard of Care Radiotherapy, Standard of Care Chemotherapy Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC NCT06162221Phase 1, Phase 298 sites๐Ÿ“ Gilbert๐Ÿ“ Duarte๐Ÿ“ Irvine Revolution Medicines, Inc. ยท Tests: RMC-6291, RMC-6236, Pembrolizumab, Cisplatin, Carboplatin Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer. NCT05378204NA25 sites๐Ÿ“ Bordeaux๐Ÿ“ Caen๐Ÿ“ Clermont-Ferrand Institut Claudius Regaud ยท Tests: Main study:, Sub-study: A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies NCT04678648Phase 13 sites๐Ÿ“ Los Angeles๐Ÿ“ Denver๐Ÿ“ Nashville RasCal Therapeutics, Inc. ยท Tests: RSC-1255 Dose Escalation, RSC-1255 Dose Expansion ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs NCT06775743Phase 21 site๐Ÿ“ Shanghai Fudan University ยท Tests: ORIENT-31 regimen, SBRT A Phase I Study of CFT8919 in Patients With Advanced NSCLC NCT06641609Phase 11 site๐Ÿ“ Hangzhou Betta Pharmaceuticals Co., Ltd. ยท Tests: Dose-Escalation (Phase Ia) CFT8919 capsule, Dose-Expansion (Phase Ib) CFT8919 capsule, Cohort-Expansion (Phase Ic) CFT8โ€ฆ Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients NCT06634199n/a22 sites๐Ÿ“ Ferrol๐Ÿ“ Alicante๐Ÿ“ Badalona Fundaciรณn GECP ยท Tests: Durvalumab A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. NCT05967689Phase 280 sites๐Ÿ“ Birmingham๐Ÿ“ Duarte๐Ÿ“ Boston Taiho Oncology, Inc. ยท Tests: TAS6417, CYP Cocktail, Transporter Cocktail A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases NCT05033691NA1 site๐Ÿ“ Jerusalem Hadassah Medical Organization ยท Tests: Stereotactic surgery A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) NCT06452277Phase 3279 sites๐Ÿ“ Newport Beach๐Ÿ“ San Diego๐Ÿ“ San Francisco Bayer ยท Tests: Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer NCT04090567Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Cediranib, Ceralasertib, Olaparib Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant NCT06543381Phase 12 sites๐Ÿ“ Duarte๐Ÿ“ Cleveland City of Hope Medical Center ยท Tests: Biospecimen Collection, Olutasidenib PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC NCT06533384Phase 31 site๐Ÿ“ Guangzhou Guangdong Provincial People's Hospital ยท Tests: As per the germline BRCA1/2 mutation status, the selection of either Fuzuloparib or capecitabine in combination with Caโ€ฆ Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis NCT04557969n/a1 site๐Ÿ“ Bethesda National Cancer Institute (NCI) A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib NCT06668103Phase 25 sites๐Ÿ“ Hefei๐Ÿ“ Harbin๐Ÿ“ Wuhan Abbisko Therapeutics Co, Ltd ยท Tests: ABSK043 in combination with Firmonertinib Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation NCT07012031Phase 1, Phase 29 sites๐Ÿ“ Sacramento๐Ÿ“ Tampa๐Ÿ“ Tampa National Cancer Institute (NCI) ยท Tests: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging Ziftomenib Maintenance Post Allo-HCT NCT06440135Phase 12 sites๐Ÿ“ Boston๐Ÿ“ Columbus Massachusetts General Hospital ยท Tests: Ziftomenib Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK NCT05266846Phase 21 site๐Ÿ“ Changsha Hunan Province Tumor Hospital ยท Tests: Pembrolizumab injection Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer NCT06995677Phase 248 sites๐Ÿ“ Homewood๐Ÿ“ Little Rock๐Ÿ“ Murrieta Tyra Biosciences, Inc ยท Tests: TYRA-300 60mg, TYRA-300 50mg, TYRA-300 Dose 70 mg A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC NCT07058519Phase 21 site๐Ÿ“ Shanghai Shanghai Chest Hospital ยท Tests: Osimertinib-based adaptive treatment, Osimertinib 80 MG Detection of the BRAF V600E Mutation in Liquid Biopsy Using the CRISPR/Cas12a System NCT07870265NA1 site๐Ÿ“ Brno Masaryk Memorial Cancer Institute ยท Tests: Novel CRISPR/Cas12a Electrochemical Bioassay, Reference Standard Molecular Diagnostics (NGS and ddPCR), Serial Peripherโ€ฆ Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation NCT05761470Phase 21 site๐Ÿ“ Guangzhou Ying Lin ยท Tests: Camrelizumab, Fluzoparib, Nab-paclitaxel Prostate Cancer Patients Treated With Alternative Radiation Oncology Strategies NCT04083937NA1 site๐Ÿ“ Heidelberg University Hospital Heidelberg ยท Tests: Hypofractionated radiotherapy with photons, Hypofractionated radiotherapy with protons, Normofractionated radiotherapy โ€ฆ Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression NCT07655622Phase 1, Phase 21 site๐Ÿ“ Nanchang Second Affiliated Hospital of Nanchang University ยท Tests: Vebreltinib, Furmonertinib 80mg PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas NCT06961565Phase 15 sites๐Ÿ“ Birmingham๐Ÿ“ St Leonards๐Ÿ“ Melbourne Pasithea Therapeutics Corp. ยท Tests: PAS-004 Tablets Study of How Safe and Effective Tarlatamab is in Brain Cancers NCT06776250Phase 21 site๐Ÿ“ Toronto University Health Network, Toronto ยท Tests: Tarlatamab
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy